Could Alnylam Pharmaceuticals, Inc. Lose Strenght? Option Traders Don’t Think So

 Could Alnylam Pharmaceuticals, Inc. Lose Strenght? Option Traders Don't Think So

In today’s session Alnylam Pharmaceuticals, Inc. (ALNY) registered an unusually high (400) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the December, 2016 call, expecting serious ALNY increase. With 400 contracts traded and 20234 open interest for the Dec, 16 contract, it seems this is a quite bullish bet. The option with symbol: ALNY161216C00055000 closed last at: $0.85 or 10.5% down. About 199,963 shares traded hands. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has declined 32.93% since April 27, 2016 and is downtrending. It has underperformed by 38.16% the S&P500.

Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on February, 9. They expect $-1.35 earnings per share, down 26.17% or $0.28 from last year’s $-1.07 per share. After $-1.21 actual earnings per share reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 11.57% negative EPS growth.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage

Out of 14 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 8 rate it a “Buy”, 0 “Sell”, while 6 “Hold”. This means 57% are positive. $184 is the highest target while $34 is the lowest. The $85.07 average target is 86.23% above today’s ($45.68) stock price. Alnylam Pharmaceuticals has been the topic of 31 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The rating was initiated by Jefferies on Friday, October 23 with “Buy”. Leerink Swann maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Tuesday, February 16 with “Outperform” rating. As per Friday, August 5, the company rating was maintained by Jefferies. JMP Securities maintained the shares of ALNY in a report on Friday, August 28 with “Outperform” rating. Credit Suisse maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Thursday, October 6 with “Outperform” rating. The rating was downgraded by Barclays Capital on Thursday, October 6 to “Equal-Weight”. The stock has “Outperform” rating given by Credit Suisse on Wednesday, January 20. On Thursday, October 6 the stock rating was downgraded by Leerink Swann to “Mkt Perform”. The company was initiated on Tuesday, August 2 by Morgan Stanley. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Hold” rating by TheStreet on Saturday, August 22.

According to Zacks Investment Research, “Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company’s leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.”

Insitutional Activity: The institutional sentiment decreased to 1.02 in 2016 Q2. Its down 0.25, from 1.27 in 2016Q1. The ratio turned negative, as 31 funds sold all Alnylam Pharmaceuticals, Inc. shares owned while 60 reduced positions. 23 funds bought stakes while 93 increased positions. They now own 72.84 million shares or 2.29% more from 71.20 million shares in 2016Q1.
Mizuho Asset Coltd last reported 1,287 shares in the company. Amp Cap Investors Ltd has 0.01% invested in the company for 19,559 shares. Moreover, Teacher Retirement Systems Of Texas has 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 5,444 shares. State Of Wisconsin Inv Board accumulated 49,790 shares or 0.01% of the stock. Swiss Natl Bank last reported 214,900 shares in the company. Delta Lloyd Nv, a Netherlands-based fund reported 5,204 shares. Prudential Inc holds 0% or 4,674 shares in its portfolio. The Massachusetts-based Somerville Kurt F has invested 0.19% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Bessemer Gru has 0% invested in the company for 55 shares. Public Employees Retirement Association Of Colorado reported 17,829 shares or 0.01% of all its holdings. Intl Grp Inc has 1,932 shares for 0% of their US portfolio. Bancorp Of New York Mellon Corporation holds 0.01% or 348,636 shares in its portfolio. Oregon Public Employees Retirement Fund last reported 0% of its portfolio in the stock. Gulf Bancorporation (Uk) Limited has 0.02% invested in the company for 23,100 shares. Meeder Asset Mngmt has invested 0.02% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Insider Transactions: Since July 19, 2016, the stock had 1 insider purchase, and 1 sale for $918,262 net activity. Shares for $1.03 million were bought by PYOTT DAVID E I. MARAGANORE JOHN sold 30,151 shares worth $1.95 million.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $3.98 billion. The Firm is engaged in developing therapeutics based on ribonucleic acid interference (RNAi). It currently has negative earnings. The Firm is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs).

ALNY Company Profile

Alnylam Pharmaceuticals, Inc., incorporated on May 8, 2003, is a biopharmaceutical company. The Firm is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). The Firm is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). The Company’s investigational RNAi therapeutics focus on Strategic Therapeutic Areas (STArs), including Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, such as dyslipidemia, hypertension, non-alcoholic steatohepatitis (NASH) and type II diabetes, and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics for the treatment of hepatic infectious diseases.

More recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Fool.com which released: “Alnylam Pharmaceuticals, Inc. Discloses Deaths, Waits for More Data” on November 04, 2016. Also Fool.com published the news titled: “Why Alnylam Pharmaceuticals, Inc. Took a 47.5% Dive in October” on November 07, 2016. Businesswire.com‘s news article titled: “Alnylam Pharmaceuticals and The Medicines Company Announce Publication of …” with publication date: November 13, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment